secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEX CORP /DE/ (IEX)
CIK:        0000832101
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0000832101-24-000004
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEX Q4 sales -3%, adjusted EPS $1.83 (-9% YoY); FY2024 adjusted EPS guidance $8.15-$8.45
--------------------------------------------------------------------------------

- Q4 sales $789M (-3%, -6% organic); GAAP EPS $1.43 (-16%), adjusted EPS $1.83 (-9%).
- Full-year record sales $3.3B, record adjusted EPS $8.22 (+1%), record free cash flow $627M.
- HST segment sales -11% YoY (-19% organic); adjusted EBITDA margin 25.8% (-450bps) on weak Life Sciences.
- Acquired STC Material Solutions for $202M in Dec 2023; divested Novotema with $9.1M loss.
- FY2024 outlook: organic sales growth 0-2%, GAAP EPS $7.15-$7.45, adjusted EPS $8.15-$8.45.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832101/000083210124000004/0000832101-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832101/000083210124000004/iex-20240206.htm
  HTML page:      https://secwatch.observer/filing/0000832101-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer